


## Nemonapride

<b>Cat. No.:</b>	HY-103415
<b>CAS No.:</b>	75272-39-8
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>26</sub> ClN <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	387.9
<b>Target:</b>	Dopamine Receptor; 5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Nemonapride is a highly potent dopamine D <sub>2</sub> receptor antagonist with a K <sub>i</sub> of 0.06 nM. Nemonapride also activates 5-HT <sub>1A</sub> receptor with an IC <sub>50</sub> of 34 nM. Nemonapride is an antipsychotic that readily passes through the blood brain barrier and exhibits potent neuroleptic effects in animals <sup>[1][2][3]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	5-HT <sub>1A</sub> Receptor 34 nM (IC <sub>50</sub> )	D <sub>2</sub> Receptor 0.06 nM (K <sub>i</sub> )

### REFERENCES

- [1]. Terai M, et al. Selective binding of YM-09151-2, a new potent neuroleptic, to D<sub>2</sub>-dopaminergic receptors. *Jpn J Pharmacol.* 1983 Aug;33(4):749-55.
- [2]. Seeman P, Van Tol HH. Dopamine receptor pharmacology. *Trends Pharmacol Sci.* 1994 Jul;15(7):264-70.
- [3]. Assié MB, et al. 5-HT<sub>1A</sub> receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. *Eur J Pharmacol.* 1997 Sep 10;334(2-3):141-7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA